Description: Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.
Home Page: www.diffusionpharma.com
DFFN Technical Analysis
300 East Main Street
Charlottesville,
VA
22902
United States
Phone:
434 220 0718
Officers
| Name | Title |
|---|---|
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Pres, CEO & Director |
| Mr. William Karl Hornung | Chief Financial Officer |
| Mr. William Robert Elder J.D. | Gen. Counsel & Corp. Sec. |
| Dr. Christopher D. Galloway M.D. | Chief Medical Officer |
| Dr. David Randolph Jones M.D. | Sr. Medical Advisor |
| Ms. Suzanne Cassidy | Sr. Director & Head of Quality Assurance |
| Dr. Jennifer Llewelyn Ph.D. | Sr. Director & Head of CMC |
| Ms. Raven Jaeger M.S. | Chief Regulatory Officer |
| Ms. Kelly Hoy | Director of Project Management |
| Mr. Harry Cook | VP of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5113 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-01-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |